Revenue segments as reported by the company.

Online Revenue

Wholesale Revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing

Operations and support

Technology and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hims & Hers Health achieves record revenue and profitability growth

Hims & Hers Health shows strong financial performance with revenue growth and profitability milestones.
The company's focus on customer-centric strategies, brand building, and innovation drives growth.
Challenges include competition in new categories and maintaining margins on personalized products.
Opportunities lie in expanding product offerings, improving customer experience, and leveraging efficiencies.

Hims & Hers Health excels in Q1 earnings, eyes strategic growth

Hims & Hers Health delivered robust financial performance in Q1 2023, driven by revenue growth, improved margins, and disciplined expense management.
The company's strengths lie in its focus on trusted brands, innovation in product offerings, and commitment to clinical excellence, fostering consumer trust and loyalty.
While challenges like insurance reimbursement and new category entries exist, they present opportunities for strategic growth and market differentiation in the healthcare sector.

Hims & Hers Health (HIMS) reports robust Q2 earnings, eyes personalized healthcare growth

Hims & Hers Health delivered strong financial performance in Q2, driven by revenue growth, expanded gross margins, and operational efficiency. While facing short-term challenges from pricing investments, the company remains focused on long-term growth through personalized treatments and new category launches. Opportunities lie in leveraging consumer trends towards personalized healthcare and expanding product offerings.

Hims & Hers Health reports robust Q3 performance and growth opportunities

Hims & Hers Health (HIMS) showcased strong performance, innovation, and resilience in Q3, driving revenue growth, subscriber base expansion, and improved profitability.
While challenges like achieving positive net income and balancing growth with new category launches exist, the company's strategic initiatives and focus on customer value creation position it for future success.
Opportunities in the weight management category, personalized products, and efficiency gains present avenues for HIMS to capitalize on market trends and enhance its competitive edge.
With a solid financial position, a clear marketing strategy, and a commitment to customer engagement, HIMS is poised for continued growth and value creation in the healthcare sector.

Hims & Hers Health reports stellar Q4 performance and growth outlook

Hims & Hers Health delivered a strong performance in Q4 2023, with robust revenue growth, positive net income, and expanded gross margins.
The company's focus on personalized solutions, subscriber growth, and financial strength positions it well for future growth and market expansion.
While facing challenges in managing costs and margin expansion, HIMS has opportunities to drive revenue growth, enhance user experience, and offer a diverse product range.
By balancing its strengths, addressing challenges, and seizing opportunities, Hims & Hers Health is poised for continued success in the healthcare market.

Hims & Hers Health reports stellar Q1 results and eyes expansion

Hims & Hers Health's Q1 2024 performance reflects strong financial growth, driven by record subscriber numbers and revenue increase, underpinned by a strategic focus on personalized care and enhancing customer experience.
The company's strengths lie in their ability to drive consumer adoption through user-friendly solutions, capitalize on the rapid growth of the Hers segment, and maintain consumer confidence through strategic pricing initiatives.
While facing challenges in scaling operations and managing increased capital expenditures, HIMS has ample opportunities to expand their offerings, invest in new product categories, and drive further revenue growth through strategic pricing adjustments.

Hims & Hers Health posts stellar Q2 results, eyes revenue diversification

Hims & Hers Health (HIMS) reported impressive Q2 performance, with strong revenue growth and subscriber additions.
The company's strategic initiatives in weight management and sterile compounded medications position it for future success.
While facing challenges in data availability and market dynamics, Hims & Hers has opportunities for revenue diversification and enhanced customer engagement.

Hims & Hers Health (HIMS) reports stellar Q3 results and eyes growth through personalized healthcare

Hims & Hers Health's Q3 performance reflects strong revenue growth, subscriber expansion, and improved profitability, positioning the company for continued success.
While facing challenges in retention and operational efficiency, the company's strategic initiatives and market positioning offer opportunities for sustained growth and innovation.
With a focus on personalized healthcare solutions and social responsibility, Hims & Hers Health is well-positioned to capitalize on market opportunities and drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hims was founded in November 2017 after Andrew Dudum was called out by his sister for having dry skin and breakouts. After she ordered him expensive products to address his issues, Dudum realized that men don't have the same options as women when it comes to purchasing wellness products. 

Now with radiant skin, Andrew Dudum and Jack Abraham co-found HIMS as an Atomic (VC fund) portfolio company. The company initially sells hair loss treatments, biotin vitamins, shampoo, and erectile dysfunction treatments. 

The company raises $7 million in Series A from M/C Partners, SV Angel and Thrive Captial, putting its pre-money valuation at $13 million.

Hims raises $40 million in Series B led by IVP and Redpoint Ventures, putting its pre-money valuation at $160 million. 

Hims launches a women's brand, Hers. 

Hers offers telemedicine services, birth control, and non-prescription hair and skin-care products. 

The company partners with A-list couple Jennifer Lopez and Alex Rodriguez, who work with the company on the launch of new products. 

Hims raises $297 million in Series C funding led by DCM Ventures, NewView Capital, McKesson Ventures, putting its valuation at $1 billion.

Hims and Hers expands into virtual mental health services led by licensed professionals, with support groups available free of charge during the COVID-19 pandemic. 

The company now provides access to medical care and treatment for more than a dozen conditions with more than 50 products, and has facilitated 1 million medical visits through its telehealth platforms in 2019. 

Hims goes public through a merger with a blank-check company Oaktree Acquisition Corp at $1.6 billion valuation.

forhims.com/aboutus
forhims.com/investors
SEC
CNBC
Business Insider
Bloomberg
Crunchbase
Axios

Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.10 per share a year ago.

Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates

Hims & Hers Health Inc. HIMS, -3.07% shares rallied nearly 13% in the aftermarket Monday after the telehealth company reported a narrower-than-expected loss for its second quarter and revenue that was above expectations. Hims & Hers lost $7.2 million, or 3 cents a share, in the quarter, compared with $19.7 million, or 10 cents a share, in the second quarter of 2022.

Hims & Hers stock jumps 13% after narrower loss in Q2

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today reported financial results for the second quarter ended June 30, 2023. “This quarter marks a significant turning point for Hims & Hers, where step-change progress was made in transforming our company from an access-oriented company, towards a platform offering a personalized patient experience,” said Andrew Dudum, co-founder and CEO.

Hims & Hers Health, Inc. Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Outlook

Hims & Hers Health has lagged the market for the past couple of months. The business is executing well and is unprofitable as it is investing heavily to grow revenue instead of earnings. A bargain valuation and strong growth outlook make shares a no-brainer for long-term investors in my view.

Hims & Hers Health: Giving Investors Another Bite At The Apple

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced a new approach to enable providers to personalize sexual health treatment for men that also supports cardiovascular health. Through Heart Health by Hims, providers will be able to personalize treatments to combine active ingredients found in clinically proven medications to address multiple conditions in one pill, demonstrating Hims & Hers'.

Hims & Hers Expands Into Cardiovascular Health with New Dual-Action Capabilities

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2023 financial results after the market closes on Monday, August 7, 2023. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, refer.

Hims & Hers to Announce Second Quarter 2023 Financial Results on August 7, 2023

Spruce Capital Management issued a short report on Hims & Hers Health, Inc., but the call actually only forecast downside risk to $5. The health and wellness company continues to grow at a fast clip while expanding the market opportunity beyond the initial ED category. The stock rallied on the news, with Hims already beaten down this year and trading at a cheap valuation.

Hims & Hers: Market Blows Off Short Report

Teladoc

Teladoc's ambition to disrupt the healthcare industry with technology and virtual care looked to be working during the pandemic - its shares rose >700%. Meanwhile, Hims & Hers launched a more pragmatic platform and IPO'd in 2021 via a SPAC. Teladoc's share price came crashing down to earth as it became obvious that its subscribers rarely used the services on offer.

Hims & Hers Vs. Teladoc: Different Approaches To 'Telemedicine' - But Only One Is Working

I recommend a buy rating due to Hims & Hers Health's strong growth, expanding EBITDA margins, and potential in the growing telehealth market. I see room for further margin expansion as HIMS increases fulfillment capacity through affiliated pharmacies. Despite competition from larger players, the Company's strong balance sheet and growing profitability position it well for future growth and potential acquisitions.

Hims & Hers Health: Expect Strong EBITDA Growth As Revenue Growth Remains Strong

Hims & Hers Health stock has fallen since its last earnings report. Wall Street could be misinterpreting the company's high marketing spend.

The More This Potential Multibagger Stock Drops, The More I Buy

Viking Therapeutics

Hims & Hers has a booming telemedicine business that could grow by 57% this year. Viking Therapeutics has a promising pipeline that features a couple of potential blockbuster drugs.

2 Hot Stocks Up 30% This Year That Wall Street Thinks Can Still Go Higher

Marqeta

Today we dive into a pocket of the stock market that many investors like to own as part of diversified portfolios: cheap stocks trading for $10 a share or less. Along with the cheap price tag, the stocks we explore today boast high Zacks Ranks given their improving earnings outlooks.

How to Find the Best Cheap Stocks Under $10 to Buy in July

Opendoor

OneSpaWorld Holdings Limited

Sun Country Airlines

Shutterstock

Sterling Check Corp

Warby Parker

Given the riskier and more speculative nature of small-cap stocks, if you own a stock in this category, it's important to keep an eye out for signs that said name has become one of the small-cap stocks to sell. A key warning sign to look out for is insider selling.

7 Small-Cap Stocks That Have Insiders Running for the Exit

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today unveiled the latest innovative additions to hair care offerings provided by Hers. Available now, the Hair Blends line provides access to formulations that are designed for women who may benefit from more personalized options to treat hair loss. Hers' market insights findings indicate that women with hair loss are highly motivated and in search of a better.

Half of Women Experience Hair Loss; Hers Unveils Innovative Line of Personalized Solutions

Hims & Hers plunged after Q2 adjusted EBITDA guidance disappointed Wall Street. The online health and wellness company has massive growth opportunities ahead and continues investing aggressively in marketing to build its subscriber base. HIMS stock is a bargain below 2x '24 sales targets for a company forecasted to maintain 25% growth while constantly providing conservative estimates.

Hims & Hers: Sell-Off Opportunity

Hims & Hers stock has struggled despite strong Q1 earnings and raised full-year guidance, with shares down over 20% since the report. HIMS' subscriber count grew 87% YoY to 1.209 million, and it is investing in brand awareness to capture more business and move into other categories such as mental health and dermatology. Questions persist about the business model and expansion into other categories, with more transparency needed to make investors more comfortable with the stock.

Hims & Hers: More Transparency Could Help The Stock

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, announced today that Hard Mints by Hims are now available for people across the United States. Hims anticipates they will also be available across the United Kingdom in June. Hard Mints by Hims is a line of chewable mint-flavored tablets that healthcare providers can prescribe for their patients to address their specific needs and experience with sexual dysfunc.

Hard Mints Now Available Nationwide

Despite Hims & Hers delivering exceptional numbers on almost all KPI metrics, the stock has dipped by ~17.5% since the release of its Q1 report earlier this month. In this note, we will discuss Hims & Hers' Q1 2023 report and re-evaluate our fair value estimate for the company.

Hims & Hers Stock: The Gift That Keeps On Giving

Direct-to-consumer healthcare is proving lucrative. This company is growing subscribers by 87% year over year.

This Healthcare Innovator Is Up 235% in 12 Months: There's More Where That Came From

HIMS delivered another record-breaking quarter as subscriptions and revenue both set new all-time highs. The company actually expanded gross margins from 74% to 80%, increased multi-month subscriptions, and generated 10% more revenue per customer than two years ago.

Hims & Hers Health: The Record-Breaking Continues

Hims & Hers Health, Inc. (NYSE:HIMS ) Q1 2023 Results Conference Call May 8, 2023 5:00 PM ET Company Participants Alice Lopatto - Vice President of Investor Relations Andrew Dudum - Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Jack Wallace - Guggenheim Securities Dan Clark - Bank of America Glen Santangelo - Jefferies Korinne Wolfmeyer - Piper Sandler Luis Mario Higuera - Citi Jailendra Singh - Truist Securities Operator Ladies gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers First Quarter 2023 Earnings Conference Call.

Hims & Hers Health, Inc. (HIMS) Q1 2023 Earnings Call Transcript

Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.08 per share a year ago.

Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Tops Revenue Estimates

Hims & Hers Health Inc. HIMS — the wellness company behind the online telehealth and prescription platforms Hims and Hers — on Monday reported a bigger per-share loss than expected for its first quarter, but raised its full-year sales forecast. The company — which offers erectile dysfunction pills, birth control, and anxiety and depression medications — said it expected full-year sales of $810 million to $830 million, compared with an earlier outlook for $735 million to $755 million and FactSet forecasts for $755.3 million.

Him & Hers raises full-year sales outlook, but stock falls

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today reported financial results for the first quarter ended March 31, 2023. “We are pleased with our outstanding performance in the first quarter, as our ability to deliver more personalized and accessible products and services is inspiring more customers to take better care of their health and well-being,” said Andrew Dudum, co-founder and CE.

Hims & Hers Health, Inc. Reports First Quarter 2023 Financial Results and Raises Full Year 2023 Outlook

Hims & Hers Health, Inc. (HIMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

News for Hims & Hers Health Stock (HIMS)